Sir,
Hydralazine can rarely induce an antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis and less than 80 such cases have been reported hitherto. 1, 2 Here, we report the case of an elderly patient who was diagnosed with hydralazine-induced ANCA vasculitis after taking hydralazine for 5 years.
A 76-year lady presented with complaints of cough and dyspnea for one day and decreased oral intake for three weeks. She had a past history of diabetes mellitus, hypertension (on hydralazine for two years) and chronic kidney disease (baseline creatinine, 1.9 mg/dl 3 months ago with history of microscopic hematuria for 18 months). Physical examination revealed pallor and decreased air entry at both lung bases. Chest radiograph showed bilateral air-space opacities and CT chest revealed consolidation of the lingula. She was started on antibiotics for pneumonia.
Laboratory investigations were notable for anemia (hemoglobin: 7.9 g/dl) and acute kidney injury (creatinine, 4.0 mg/dl). Renal ultrasonography showed bilaterally increased renal parenchymal echogenicity. Urine microscopy showed red cell casts; and urine protein-to-creatinine ratio was consistent with nonnephrotic range proteinuria (300 mg/day). Auto-immune work-up for glomerulonephritis was requested, which was significant for anti-neutrophilantibody (ANA): positive at a dilution of 1:1280 (homogeneous pattern); anti-dsDNA antibody titer: elevated (907 IU/L); ANCA: positive (peri-nuclear pattern); and anti-myeloperoxidase (MPO) antibody titer: elevated (104 AU/mL).
Rest of the auto-immune work-up was within normal limits (Table I) . Renal biopsy was performed (Figure 1 ), which demonstrated a pauci-immune, diffuse necrotizing, crescentic glomerulonephritis.
Based on clinical, serological and pathological findings, a diagnosis of hydralazine-induced MPO-ANCA vasculitis (renal-limited) was made. Hydralazine was stopped immediately and aggressive treatment was initiated with a combination of plasmapheresis and pulse-dose steroids. Plan was to start rituximab therapy as outpatient. Patient's renal function tests had stabilized at the time of discharge and they continued to improve on follow-up.
This patient had evidence of acute kidney injury on top of chronic kidney disease (microscopic hematuria for 18 months) while taking hydralazine for 2 years. Renal biopsy revealed a pauci-immune crescentic glomerulonephritis. Although an idiopathic ANCA vasculitis could cause similar pathologic findings, the combination of exposure to hydralazine (a drug known to cause MPO-ANCA vasculitis), serologic detection of MPO-ANCA, and elevated ANA and anti-dsDNA antibody titers in the absence of clinical manifestations of lupus were all consistent with hydralazine-induced MPO-ANCA vasculitis. 3 Priming of neutrophils, for instance, due to an infection, is known to exacerbate ANCA-mediated vasculitides. 4 In this case, the patient had evidence of pneumonia, which may have exacerbated an ongoing vasculitic process. Elevated anti-dsDNA antibody titers were observed in this case, which are uncommonly seen in hydralazine-induced ANCA vasculitis. 2 
